Forbes November 1, 2023
A Centers for Medicare and Medicaid decision memorandum issued last month lifts restrictions on coverage of Alzheimer’s disease diagnostics that measure beta amyloid plaque in the brain. Excessive levels of plaque are considered an indicator of the presence of Alzheimer’s disease. Facilitating reimbursement of diagnostic tests is critical in light of recent approvals of drugs intended to reduce amyloid plaque. But questions remain regarding equitable access, as coverage decisions will now be made at the local level by Medicare Administrative Contractors.
Alzheimer’s disease is the most common cause of dementia, accounting for 60-80% of all cases in the U.S. It is clinically diagnosed based on the presence of cognitive impairment that severely interferes with the activities of daily living.
A...
Today's Sponsors
Today's Sponsor